FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

| STATEMENT | OF CHANGES | IN BENEFICIAL | OWNERSHIP |
|-----------|------------|---------------|-----------|
|           |            |               |           |

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* HUNDMEJEAN MARTINA  |         |                          |                   |                 |                  | 2. Issuer Name and Ticker or Trading Symbol COLGATE PALMOLIVE CO [ CL ] |                  |      |  |  |                    |  |  | heck all ap                             | ctor  | Ü                    | 10% O  | wner                                     |
|--|---------|--------------------------|-------------------|-----------------|------------------|---|------------------|------|--|--|--------------------|--|--|---|---|----------------------|--|--|
|  | ,       | LMOLIVE CON              | (Middle)<br>MPANY |                 |                  | 3. Date of Earliest Transaction (Month/Day/Year) 05/09/2022             |                  |      |  |  |                    |  |  | Offic<br>belo                           | er (give title<br>w)  |                      |  | specify                                  |
| (Street) NEW YO  | ORK N   | Y                        | 10022<br>(Zip)    |                 | _   4. If        | f Amei  | ndment,          | Date | of Origina                                       | al File  | d (Month/D         | ay/Year)   |  | ne)<br>X For                            | or Joint/Grou<br>m filed by Or<br>m filed by Mo<br>son            | ne Rep               | orting Perso   | on                                       |
|  |         | Tab                      | le I - No         | n-Deriv         | /ative           | Sec   | uritie           | s Ac | quired   | , Dis  | posed o            | of, or Bo  | eneficia                               | lly Own                                 | ed  |                      |  |  |
| 1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)  |         |                          |                   | Execution Date, |                  | Transaction Disposed C  |                  |      | ies Acquired (A) or<br>Of (D) (Instr. 3, 4 and ! |  | d 5) Secu<br>Bene  | icially<br>d Following   | Forn<br>(D) d                          | n: Direct<br>or Indirect<br>nstr. 4)    | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |                      |  |  |
|  |         |                          |                   |                 |                  |   |                  | Code | v  | Amount   | (A) o              | Price  | Trans                                  | action(s)<br>3 and 4)                   | tion(s)   |                      | (1134.4)   |  |
| Common Stock 05/09/2   |         |                          |                   | /2022           | 2022             |   | A <sup>(1)</sup> |      | 2,317  | 7 A \$0.   |                    | 000  | 6,147                                  |   | D   |                      |  |  |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) |         |                          |                   |                 |                  |   |                  |      |  |  |                    |  |  |   |   |                      |  |  |
| 1. Title of Derivative Security (Instr. 3) Price of Derivative Security  |         | se (Month/Day/Year) if a |                   | n Date,         |                  | Transaction<br>Code (Instr.   |                  | of E |  | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | 7. Title and<br>Amount of<br>Securities<br>Underlying<br>Derivative Security<br>(Instr. 3 and 4) |  | 8. Price Derivative Security (Instr. 5) |   | e<br>es<br>ally<br>g | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | Beneficial<br>Ownership<br>ct (Instr. 4) |
|  |         |                          |                   |                 | Code             | v   | (A)              | (D)  | Date<br>Exercisal                                |  | Expiration<br>Date | Title  | Amount<br>or<br>Number<br>of<br>Shares |   |   |                      |  |  |
| Stock<br>Option<br>(Right to   | \$77.67 | 05/09/2022               |                   |                 | A <sup>(2)</sup> |   | 3,122            |      | (3)  |  | 05/09/2030         | Common<br>Stock  | 3,122                                  | \$0.0000                                | 3,12  | 2                    | D  |  |

## Explanation of Responses:

- 1. Annual director stock grant under the issuer's incentive compensation plan, credited to a stock unit account pursuant to the issuer's incentive compensation plan.
- 2. Annual director stock option grant under the issuer's incentive compensation plan.
- 3. Option becomes exercisable in equal annual installments over three years beginning on the first anniversary of the May 9, 2022 grant date.

/s/ Kristine Hutchinson, 05/11/2022 Attorney-in-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.